Cargando…
Risk Assessment and Pancreatic Cancer: Diagnostic Management and Artificial Intelligence
SIMPLE SUMMARY: Pancreatic cancer (PC) is one of the deadliest cancers. Its high mortality rate is correlated with several explanations; the main one is the late disease stage at which the majority of patients are diagnosed. Since surgical resection has been recognised as the only curative treatment...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9857317/ https://www.ncbi.nlm.nih.gov/pubmed/36672301 http://dx.doi.org/10.3390/cancers15020351 |
_version_ | 1784873840877240320 |
---|---|
author | Granata, Vincenza Fusco, Roberta Setola, Sergio Venanzio Galdiero, Roberta Maggialetti, Nicola Silvestro, Lucrezia De Bellis, Mario Di Girolamo, Elena Grazzini, Giulia Chiti, Giuditta Brunese, Maria Chiara Belli, Andrea Patrone, Renato Palaia, Raffaele Avallone, Antonio Petrillo, Antonella Izzo, Francesco |
author_facet | Granata, Vincenza Fusco, Roberta Setola, Sergio Venanzio Galdiero, Roberta Maggialetti, Nicola Silvestro, Lucrezia De Bellis, Mario Di Girolamo, Elena Grazzini, Giulia Chiti, Giuditta Brunese, Maria Chiara Belli, Andrea Patrone, Renato Palaia, Raffaele Avallone, Antonio Petrillo, Antonella Izzo, Francesco |
author_sort | Granata, Vincenza |
collection | PubMed |
description | SIMPLE SUMMARY: Pancreatic cancer (PC) is one of the deadliest cancers. Its high mortality rate is correlated with several explanations; the main one is the late disease stage at which the majority of patients are diagnosed. Since surgical resection has been recognised as the only curative treatment, a PC diagnosis at the initial stage is believed the main tool to improve survival. Therefore, patient stratification according to familial and genetic risk and the creation of screening protocol by using minimally invasive diagnostic tools would be appropriate. ABSTRACT: Pancreatic cancer (PC) is one of the deadliest cancers, and it is responsible for a number of deaths almost equal to its incidence. The high mortality rate is correlated with several explanations; the main one is the late disease stage at which the majority of patients are diagnosed. Since surgical resection has been recognised as the only curative treatment, a PC diagnosis at the initial stage is believed the main tool to improve survival. Therefore, patient stratification according to familial and genetic risk and the creation of screening protocol by using minimally invasive diagnostic tools would be appropriate. Pancreatic cystic neoplasms (PCNs) are subsets of lesions which deserve special management to avoid overtreatment. The current PC screening programs are based on the annual employment of magnetic resonance imaging with cholangiopancreatography sequences (MR/MRCP) and/or endoscopic ultrasonography (EUS). For patients unfit for MRI, computed tomography (CT) could be proposed, although CT results in lower detection rates, compared to MRI, for small lesions. The actual major limit is the incapacity to detect and characterize the pancreatic intraepithelial neoplasia (PanIN) by EUS and MR/MRCP. The possibility of utilizing artificial intelligence models to evaluate higher-risk patients could favour the diagnosis of these entities, although more data are needed to support the real utility of these applications in the field of screening. For these motives, it would be appropriate to realize screening programs in research settings. |
format | Online Article Text |
id | pubmed-9857317 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98573172023-01-21 Risk Assessment and Pancreatic Cancer: Diagnostic Management and Artificial Intelligence Granata, Vincenza Fusco, Roberta Setola, Sergio Venanzio Galdiero, Roberta Maggialetti, Nicola Silvestro, Lucrezia De Bellis, Mario Di Girolamo, Elena Grazzini, Giulia Chiti, Giuditta Brunese, Maria Chiara Belli, Andrea Patrone, Renato Palaia, Raffaele Avallone, Antonio Petrillo, Antonella Izzo, Francesco Cancers (Basel) Review SIMPLE SUMMARY: Pancreatic cancer (PC) is one of the deadliest cancers. Its high mortality rate is correlated with several explanations; the main one is the late disease stage at which the majority of patients are diagnosed. Since surgical resection has been recognised as the only curative treatment, a PC diagnosis at the initial stage is believed the main tool to improve survival. Therefore, patient stratification according to familial and genetic risk and the creation of screening protocol by using minimally invasive diagnostic tools would be appropriate. ABSTRACT: Pancreatic cancer (PC) is one of the deadliest cancers, and it is responsible for a number of deaths almost equal to its incidence. The high mortality rate is correlated with several explanations; the main one is the late disease stage at which the majority of patients are diagnosed. Since surgical resection has been recognised as the only curative treatment, a PC diagnosis at the initial stage is believed the main tool to improve survival. Therefore, patient stratification according to familial and genetic risk and the creation of screening protocol by using minimally invasive diagnostic tools would be appropriate. Pancreatic cystic neoplasms (PCNs) are subsets of lesions which deserve special management to avoid overtreatment. The current PC screening programs are based on the annual employment of magnetic resonance imaging with cholangiopancreatography sequences (MR/MRCP) and/or endoscopic ultrasonography (EUS). For patients unfit for MRI, computed tomography (CT) could be proposed, although CT results in lower detection rates, compared to MRI, for small lesions. The actual major limit is the incapacity to detect and characterize the pancreatic intraepithelial neoplasia (PanIN) by EUS and MR/MRCP. The possibility of utilizing artificial intelligence models to evaluate higher-risk patients could favour the diagnosis of these entities, although more data are needed to support the real utility of these applications in the field of screening. For these motives, it would be appropriate to realize screening programs in research settings. MDPI 2023-01-05 /pmc/articles/PMC9857317/ /pubmed/36672301 http://dx.doi.org/10.3390/cancers15020351 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Granata, Vincenza Fusco, Roberta Setola, Sergio Venanzio Galdiero, Roberta Maggialetti, Nicola Silvestro, Lucrezia De Bellis, Mario Di Girolamo, Elena Grazzini, Giulia Chiti, Giuditta Brunese, Maria Chiara Belli, Andrea Patrone, Renato Palaia, Raffaele Avallone, Antonio Petrillo, Antonella Izzo, Francesco Risk Assessment and Pancreatic Cancer: Diagnostic Management and Artificial Intelligence |
title | Risk Assessment and Pancreatic Cancer: Diagnostic Management and Artificial Intelligence |
title_full | Risk Assessment and Pancreatic Cancer: Diagnostic Management and Artificial Intelligence |
title_fullStr | Risk Assessment and Pancreatic Cancer: Diagnostic Management and Artificial Intelligence |
title_full_unstemmed | Risk Assessment and Pancreatic Cancer: Diagnostic Management and Artificial Intelligence |
title_short | Risk Assessment and Pancreatic Cancer: Diagnostic Management and Artificial Intelligence |
title_sort | risk assessment and pancreatic cancer: diagnostic management and artificial intelligence |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9857317/ https://www.ncbi.nlm.nih.gov/pubmed/36672301 http://dx.doi.org/10.3390/cancers15020351 |
work_keys_str_mv | AT granatavincenza riskassessmentandpancreaticcancerdiagnosticmanagementandartificialintelligence AT fuscoroberta riskassessmentandpancreaticcancerdiagnosticmanagementandartificialintelligence AT setolasergiovenanzio riskassessmentandpancreaticcancerdiagnosticmanagementandartificialintelligence AT galdieroroberta riskassessmentandpancreaticcancerdiagnosticmanagementandartificialintelligence AT maggialettinicola riskassessmentandpancreaticcancerdiagnosticmanagementandartificialintelligence AT silvestrolucrezia riskassessmentandpancreaticcancerdiagnosticmanagementandartificialintelligence AT debellismario riskassessmentandpancreaticcancerdiagnosticmanagementandartificialintelligence AT digirolamoelena riskassessmentandpancreaticcancerdiagnosticmanagementandartificialintelligence AT grazzinigiulia riskassessmentandpancreaticcancerdiagnosticmanagementandartificialintelligence AT chitigiuditta riskassessmentandpancreaticcancerdiagnosticmanagementandartificialintelligence AT brunesemariachiara riskassessmentandpancreaticcancerdiagnosticmanagementandartificialintelligence AT belliandrea riskassessmentandpancreaticcancerdiagnosticmanagementandartificialintelligence AT patronerenato riskassessmentandpancreaticcancerdiagnosticmanagementandartificialintelligence AT palaiaraffaele riskassessmentandpancreaticcancerdiagnosticmanagementandartificialintelligence AT avalloneantonio riskassessmentandpancreaticcancerdiagnosticmanagementandartificialintelligence AT petrilloantonella riskassessmentandpancreaticcancerdiagnosticmanagementandartificialintelligence AT izzofrancesco riskassessmentandpancreaticcancerdiagnosticmanagementandartificialintelligence |